SOPHIA ANTIPOLIS, France – December 16, 2025 │ KnowMade, a leading provider of patent analysis services, is pleased to present its latest report, Cancer & Antibody Conjugates Patent Landscape Analysis 2025. The comprehensive report offers a thorough examination of the competitive landscape of Antibody Conjugates (antibody-drug conjugates, or ADC, and radioimmunoconjugates) for cancer treatment from a patent perspective, providing crucial insights for stakeholders and decision-makers.
A technological trend to watch
Antibody conjugates, including ADCs and radiolabeled antibodies, combine the targeting precision of antibodies with the potency of highly cytotoxic drugs or radionuclides. Over the last decade, this modality has moved from proof-of-concept to a major class of anti-cancer agents, with around 15 ADCs now approved worldwide and more than one hundred in clinical development. KnowMade’s Cancer & Antibody Conjugates patent report provides a comprehensive mapping of inventions related to ADCs and radioimmunoconjugates for all cancer types, hematological and solid cancers. It highlights the key patent owners, IP newcomers and their strategic IP positions that will shape the next generation of targeted oncology therapies.
Key highlights of the report
Patent Analysis: The report provides an evaluation of the global patent landscape related to Antibody Conjugates for cancer treatment, encompassing patent filing trends, geographical distribution, and legal status.
Competitive Intelligence: The identification and profiling of significant IP players, such as established patent assignees and emerging patent applicants, shows their R&D focus and strategic positioning.
Technological Innovations: An exploration of the most recent technological advances and innovative approaches in Cancer & Antibody Conjugates, with a focus on ongoing R&D efforts and potential future directions.
Market Implications: Exploration of the mechanisms of action and therapeutic effects of Cancer & Antibody Conjugates patents, including antibody targets, cytotoxic payloads and chemical linkers.
Strategic Guidance: Industrials can make informed strategic decisions regarding R&D investments, IP portfolio management, and competitive positioning with actionable intelligence.
Dr. Fabienne Massa, Scientific Analyst at KnowMade, remarked, “Antibody conjugates are reshaping oncology. Today, we see a dual dynamic: on one side, a growing list of approved ADCs for both hematologic and solid tumors; on the other, an intense patent race around next-generation payloads, linker technologies and radioimmunoconjugates. By analyzing more than 3,700 inventions, our new report helps companies understand where the field is heading and how IP will condition future therapeutic strategies in cancer.”
The Cancer & Antibody Conjugates Patent Landscape Analysis 2025 report is an essential resource for pharmaceutical companies, IP professionals, investors, and technology developers aiming to gain a competitive edge in the Antibody Conjugates domain.
Press contact
contact@knowmade.fr
Le Drakkar, 2405 route des Dolines, 06560 Valbonne Sophia Antipolis, France
www.knowmade.com
About the author
Fabienne Massa, PhD., works for KnowMade in the field of Biotechnology and Life Sciences. She holds a PhD in Molecular and Cellular Biology from the IPMC (Sophia Antipolis, France). She also holds a Master of Business Management from IAE (Nice, France) and she previously worked in the pharmaceutical industry.
About KnowMade
KnowMade is a technology intelligence and IP strategy consulting company specialized in analyzing patents and scientific publications. The company helps innovative companies, investors, and R&D organizations to understand competitive landscape, follow technological evolutions, reduce uncertainties, and identify opportunities and risks in terms of technology and intellectual property.
KnowMade’s analysts combine their strong technology expertise and in-depth knowledge of patents with powerful analytics tools and methodologies to turn patent information and scientific literature into actionable insights, providing high added value reports for decision makers working in R&D, innovation strategy, intellectual property, and marketing. Our experts provide prior art search, patent landscape analysis, freedom-to-operate analysis, IP due diligence, and monitoring services.
KnowMade has a solid expertise in Compound Semiconductors, Power Electronics, Batteries, RF Technologies & Wireless Communications, Solid-State Lighting & Display, Photonics, Memories, MEMS & Sensors, Semiconductor Packaging, Medical Devices, Medical Imaging, Microfluidics, Biotechnology, Pharmaceutics, and Agri-Food.